No Data
No Data
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $15
CCORF analyst John Newman maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 38.5% and a tot
Analysts Conflicted on These Healthcare Names: Seres Therapeutics (MCRB) and Immunocore Holdings (IMCR)
Seres Therapeutics(MCRB.US) Officer Sells US$882.66 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer von Moltke Lisa sold 939 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $882.66.Source: Announcement What is statement o
Seres Therapeutics(MCRB.US) Officer Sells US$2,288.9 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Shaff Eric D. sold 2,435 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $2,288.9.Source: Announcement What is statement
Seres Therapeutics(MCRB.US) Officer Sells US$660.82 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Young Teresa L. sold 703 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $660.82.Source: Announcement What is statement o
Seres Therapeutics(MCRB.US) Officer Sells US$837.54 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Henn Matthew R. sold 891 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $837.54.Source: Announcement What is statement o
No Data